| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Loreto Carmona | Q56419499 |
| José Ramón Maneiro | Q57029476 | ||
| P2093 | author name string | Juan J Gomez-Reino | |
| Eva Salgado | |||
| P2860 | cites work | Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT | Q21142738 |
| STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells | Q24305016 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 | ||
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration | Q27860581 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis | Q28294375 | ||
| Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir | Q28477930 | ||
| Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function | Q30485959 | ||
| Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. | Q33382517 | ||
| KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase | Q33390326 | ||
| Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment | Q33668201 | ||
| Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study | Q34301521 | ||
| Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. | Q34402406 | ||
| Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial | Q34906164 | ||
| The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo | Q34989826 | ||
| A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease | Q35489187 | ||
| Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial | Q35579238 | ||
| Kinase inhibitors: a new class of antirheumatic drugs | Q36277831 | ||
| The SYK tyrosine kinase: a crucial player in diverse biological functions | Q36662082 | ||
| Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition | Q36800953 | ||
| Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study | Q37270882 | ||
| "Go upstream, young man": lessons learned from the p38 saga | Q37649076 | ||
| The structural basis for control of eukaryotic protein kinases | Q38000674 | ||
| Selective JAK1 inhibitor and selective Tyk2 inhibitor patents | Q38042734 | ||
| Therapeutic targeting of c-KIT in cancer | Q38057806 | ||
| The riddle of the mast cell: kit(CD117)-ligand as the missing link? | Q40388512 | ||
| Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. | Q40530140 | ||
| A multitude of kinases--which are the best targets in treating rheumatoid arthritis? | Q40840109 | ||
| A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract | Q41021396 | ||
| cAMP-dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer | Q42844060 | ||
| Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. | Q43048581 | ||
| Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results | Q43223134 | ||
| Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders | Q43233025 | ||
| Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. | Q45926675 | ||
| Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. | Q45930884 | ||
| Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. | Q46030933 | ||
| Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy | Q46055998 | ||
| An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents | Q46066669 | ||
| Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis | Q46140186 | ||
| Inhibition of p38: has the fat lady sung? | Q46140191 | ||
| Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial | Q46271720 | ||
| The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling | Q46438489 | ||
| A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family | Q48366626 | ||
| Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. | Q54589616 | ||
| Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: does variable inhibition of interleukin-6 production limit effectiveness in vivo? | Q54665731 | ||
| Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis | Q58912330 | ||
| ??? | Q28295371 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| systematic review | Q1504425 | ||
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | 871-882 | |
| P577 | publication date | 2013-04-18 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis | |
| P478 | volume | 73 |
| Q28552367 | A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation |
| Q33930795 | Advances in kinase inhibition: treating rheumatic diseases and beyond |
| Q54977224 | Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients? |
| Q38837769 | Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster |
| Q55027042 | Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway. |
| Q38181051 | Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis |
| Q36055527 | Common γ-chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis |
| Q90370698 | Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation |
| Q40267179 | Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies |
| Q35020811 | Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. |
| Q26744783 | Emerging Roles of the Mitogen and Stress Activated Kinases MSK1 and MSK2 |
| Q38188862 | Emerging immunotherapies for rheumatoid arthritis. |
| Q38695599 | Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options. |
| Q47338654 | European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib |
| Q40699579 | Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials |
| Q26772850 | Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studies |
| Q48018323 | Inhibitory effect of JAK inhibitor on mechanical stress-induced protease expression by human articular chondrocytes |
| Q30689247 | Intracellular targets : current data on effectiveness and safety profile |
| Q42537908 | Oral janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib |
| Q38427697 | Proteasome inhibitors as experimental therapeutics of autoimmune diseases |
| Q37353700 | Rheumatoid factors: clinical applications |
| Q34409073 | Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now? |
| Q28084309 | Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials |
| Q33620537 | Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond |
| Q35854103 | The effect of RO3201195 and a pyrazolyl ketone P38 MAPK inhibitor library on the proliferation of Werner syndrome cells. |
| Q34858352 | The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis |
Search more.